Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hallucinations in Parkinson disease

Nature Reviews Neurology volume 5, pages 331–342 (2009)Cite this article

Abstract

Patients with Parkinson disease (PD) can experience hallucinations (spontaneous aberrant perceptions) and illusions (misinterpretations of real perceptual stimuli). Of such phenomena, visual hallucinations (VHs) and illusions are the most frequently encountered, although auditory, olfactory and tactile hallucinations can also occur. In cross-sectional studies, VHs occur in approximately one-third of patients, but up to three-quarters of patients might develop VHs during a 20-year period. Hallucinations can have substantial psychosocial effects and, historically, were the main reason for placing patients in nursing homes. Concomitant or overlapping mechanisms are probably active during VHs, and these include the following: central dopaminergic overactivity and an imbalance with cholinergic neurotransmission; dysfunction of the visual pathways, including specific PD-associated retinopathy and functional alterations of the extrastriate visual pathways; alterations of brainstem sleep–wake and dream regulation; and impaired attentional focus. Possible treatments include patient-initiated coping strategies, a reduction of antiparkinson medications, atypical neuroleptics and, potentially, cholinesterase inhibitors. Evidence-based studies, however, only support the use of one atypical neuroleptic, clozapine, and only in patients without dementia. Better phenomenological discrimination, combined with neuroimaging tools, should refine therapeutic options and improve prognosis. The aim of this Review is to present epidemiological, phenomenological, pathophysiological and therapeutic aspects of hallucinations in PD.

Key Points

  • According to cross-sectional studies, one-third of individuals with Parkinson disease (PD) experience visual hallucinations; however, up to 75% of patients will develop such phenomona over a 20-year period

  • Hallucinations have substantial psychosocial effects and are a prominent factor influencing the placement of patients with PD in nursing homes

  • Hallucinations usually occur in the context of dopaminergic or anticholinergic drug therapy for PD

  • Multifaceted visual deficits, sleep–wake cycle dysregulation and cognitive dysfunction are increasingly recognized as contributory factors to hallucinations in PD

  • Treatments for hallucinations include atypical neuroleptics and, possibly, cholinesterase inhibitors

  • In the future, a more discriminative phenomenological exploration could delineate distinct types of hallucinations with differing pathophysiological mechanisms, treatment strategies, and prognoses

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Subject of visual illusions in PD.
Figure 2: Functional MRI in patients with PD and visual hallucinations.

References

  1. Fénelon, G., Goetz, C. G. & Karenberg, A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66, 93–98 (2006).

    Article  PubMed  Google Scholar 

  2. Moskovitz, C., Moses, H. 3rd & Klawans, H. L. Levodopa induced psychosis: a kindling phenomenon. Am. J. Psychiatry 135, 669–675 (1978).

    Article  CAS  PubMed  Google Scholar 

  3. Onofrj, M. et al. Visual hallucinations in Parkinson's disease: clues to separate origins. J. Neurol. Sci. 248, 143–150 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Mjönes, H. Paralysis Agitans. A Clinical and Genetic Study (Ejnar Munksgaard, Copenhagen, 1949).

    Google Scholar 

  5. Schwab, R. S., Fabing, H. D. & Prichard, J. S. Psychiatric symptoms and syndromes in Parkinson's disease. Am. J. Psychiatry 107, 901–907 (1951).

    Article  CAS  PubMed  Google Scholar 

  6. Sacks, O. W., Kohl, M. S., Messeloff, C. R. & Schwartz, W. F. Effects of levodopa in parkinsonian patients with dementia. Neurology 22, 516–519 (1972).

    Article  CAS  PubMed  Google Scholar 

  7. Celesia, G. G. & Wanamaker, W. M. Psychiatric disturbances in Parkinson's disease. Dis. Nerv. Syst. 33, 577–583 (1972).

    CAS  PubMed  Google Scholar 

  8. Goetz, C. G. Hallucinations in Parkinson's disease: the clinical syndrome. Adv. Neurol. 80, 419–423 (1999).

    CAS  PubMed  Google Scholar 

  9. Golden, W. E., Lavender, R. C. & Metzer, E. S. Acute postoperative confusion and hallucinations in Parkinson's disease. Ann. Intern. Med. 111, 218–222 (1989).

    Article  CAS  PubMed  Google Scholar 

  10. Lippa, C. F. et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812–819 (2007).

    Article  CAS  PubMed  Google Scholar 

  11. Mosimann, U. P. et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am. J. Geriatr. Psychiatry 14, 153–160 (2006).

    Article  PubMed  Google Scholar 

  12. Diederich, N. J., Pieri, V. & Goetz, C. G. Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenetic comparison [German]. Fortschr. Neurol. Psychiat. 68, 129–136 (2000).

    Article  CAS  PubMed  Google Scholar 

  13. Barnes, J. & David, A. S. Visual hallucinations in Parkinson's disease: a review and phenomenlogical survey. J. Neurol. Neurosurg. Psychiatry 70, 727–733 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Holroyd, S., Currie, L. & Wooten, G. F. Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70, 734–738 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Fénelon, G., Mahieux, F., Huon, R. & Ziégler, M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 123, 733–745 (2000).

    Article  PubMed  Google Scholar 

  16. Graham, J. M., Grünewald, R. A. & Sagar, H. J. Hallucinosis in idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 63, 434–440 (1997).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Inzelberg, R., Kipervasser, S. & Korczyn, A. D. Auditory hallucinations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64, 533–535 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fénelon. G., Thobois, S., Bonnet, A. M., Broussolle, E. & Tison, F. Tactile hallucinations in Parkinson's disease. J. Neurol. 249, 1699–1703 (2002).

    Article  PubMed  Google Scholar 

  19. Chou, K. et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin. Neuropharmacol. 28, 215–219 (2005).

    Article  CAS  PubMed  Google Scholar 

  20. Goetz, C. G., Wuu, J., Curgian, L. & Leurgans, S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov. Disord. 21, 267–270 (2006).

    Article  PubMed  Google Scholar 

  21. Marsh, L. et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63, 293–300 (2004).

    Article  CAS  PubMed  Google Scholar 

  22. Kiziltan, G., Ozekmekçi, S., Ertan, S., Ertan, T. & Erginöz, E. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease. J. Neurol. 254, 448–452 (2007).

    Article  PubMed  Google Scholar 

  23. Goetz, C. G., Wuu, J., Curgian, L. M. & Leurgans, S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 64, 81–86 (2005).

    Article  PubMed  Google Scholar 

  24. Pagonabarraga, J. et al. A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov. Disord. 23, 443–448 (2008).

    Article  PubMed  Google Scholar 

  25. Ravina, B. et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov. Disord. 22, 1061–1068 (2007).

    Article  PubMed  Google Scholar 

  26. Miyasaki, J. M. et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66, 996–1002 (2006).

    Article  CAS  PubMed  Google Scholar 

  27. Fernandez, H. H. et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov. Disord. 23, 484–500 (2008).

    Article  PubMed  Google Scholar 

  28. Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).

    Article  PubMed  Google Scholar 

  29. Williams, D. R., Warren, J. D. & Lees, A. J. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J. Neurol. Neurosurg. Psychiatry 79, 652–655 (2008).

    Article  CAS  PubMed  Google Scholar 

  30. Haeske-Dewick, H. C. Hallucinations in Parkinson's disease: characteristics and associated features. Int. J. Geriatr. Psych. 10, 487–495 (1995).

    Article  Google Scholar 

  31. Aarsland, D., Larsen, J. P., Cummins, J. L. & Laake, K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study. Arch. Neurol. 56, 595–601 (1999).

    Article  CAS  PubMed  Google Scholar 

  32. Biglan, K. M., Holloway, R. G. Jr, McDermott, M. P., Richard, I. H. & Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 69, 187–195 (2007).

    Article  PubMed  Google Scholar 

  33. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837–844 (2008).

    Article  PubMed  Google Scholar 

  34. Goetz, C. G., Leurgans, S., Pappert, E. J., Raman, R. & Stemer, A. B. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 57, 2078–2082 (2001).

    Article  CAS  PubMed  Google Scholar 

  35. Goetz, C. G., Fan, W., Leurgans, S., Bernard, B. & Stebbins, G. T. The malignant course of “benign hallucinations” in Parkinson disease. Arch. Neurol. 63, 713–716 (2006).

    Article  PubMed  Google Scholar 

  36. McKinlay, A. et al. A profile of neuropsychiatric problems and their relationship to quality of lifefor PD patients without dementia. Parkinsonism Relat. Disord. 14, 37–42 (2008).

    Article  CAS  PubMed  Google Scholar 

  37. Goetz, C. G. & Stebbins, G. T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43, 2227–2229 (1993).

    Article  CAS  PubMed  Google Scholar 

  38. Aarsland, D., Larsen, J. P., Tandberg, E. & Laake, K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J. Am. Geriatr. Soc. 48, 938–942 (2000).

    Article  CAS  PubMed  Google Scholar 

  39. Factor, S. A. et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60, 1756–1761 (2003).

    Article  CAS  PubMed  Google Scholar 

  40. Hobson, P. & Meara, J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov. Disord. 19, 1043–1049 (2004).

    Article  PubMed  Google Scholar 

  41. Galvin, J. E., Pollack, J. & Morris, J. C. Clinical phenotype of Parkinson disease dementia. Neurology 67, 1605–1611 (2006).

    Article  PubMed  Google Scholar 

  42. Merims, D. et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J. Neural Transm. 111, 1447–1453 (2004).

    Article  CAS  PubMed  Google Scholar 

  43. Sanchez-Ramos, J. R., Ortoll, R. & Paulson, G. W. Visual hallucinations associated with Parkinson's disease. Arch. Neurol. 53, 1265–1268 (1996).

    Article  CAS  PubMed  Google Scholar 

  44. Goetz, C. G. et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50, 515–517 (1998).

    Article  CAS  PubMed  Google Scholar 

  45. Baker, W. L. et al. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat. Disord. doi:10.1016/j.parkreldis.2008.07.004 (2008).

  46. Goetz, C. G., Tanner, C. M. & Klawans, H. L. Pharmacology of hallucinations induced by long-term drug therapy. Am. J. Psych. 139, 494–497 (1982).

    Article  CAS  Google Scholar 

  47. Perry, E. K. et al. Evidence of a monoaminergic- cholinergic imbalance related to visual hallucinations in Lewy Body Dementia. J. Neurochem. 55, 1454–1456 (1990).

    Article  CAS  PubMed  Google Scholar 

  48. Harding, A. J., Broe, G. A. & Halliday, G. M. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125, 391–403 (2002).

    Article  CAS  PubMed  Google Scholar 

  49. Perry, E. K. et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis. Assoc. Disord. 4, 87–95 (1990).

    Article  CAS  PubMed  Google Scholar 

  50. Ballard, C. et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann. Neurol. 48, 868–876 (2000).

    Article  CAS  PubMed  Google Scholar 

  51. Francis, P. T. & Perry, E. K. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov. Disord. 22 (Suppl. 17), S351–S357 (2007).

    Article  PubMed  Google Scholar 

  52. Perry, E. K. & Perry, R. H. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 28, 240–258 (1995).

    Article  CAS  PubMed  Google Scholar 

  53. Sarter, M. & Bruno, J. P. Cortical acetylcholine, reality distortion, schizophrenia, and Lewy Body Dementia: too much or too little cortical acetylcholine? Brain Cogn. 38, 297–316 (1998).

    Article  CAS  PubMed  Google Scholar 

  54. Birkmayer, W. & Birkmayer, J. D. Dopamine action and disorders of neurotransmitter balance. Gerontology 33, 168–171 (1987).

    Article  CAS  PubMed  Google Scholar 

  55. Beasley, B. L., Nutt, J. G., Davenport, R. W. & Chase, T. N. Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch. Neurol. 37, 155–156 (1980).

    Article  CAS  PubMed  Google Scholar 

  56. Rabey, J. M., Vardi, J., Askenazi, J. J. & Streifler, M. L-tryptophan administration in L-dopa induced hallucinations in elderly Parkinsonian patients. Gerontology 23, 438–444 (1977).

    Article  CAS  PubMed  Google Scholar 

  57. Abbas, A. & Roth, B. L. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin. Pharmacother. 9, 3251–3259 (2008).

    Article  CAS  PubMed  Google Scholar 

  58. de Maindreville, A. D., Fénelon, G. & Mahieux, F. Hallucinations in Parkinson's disease: a follow-up study. Mov. Disord. 20, 212–217 (2005).

    Article  PubMed  Google Scholar 

  59. Nebe, A. & Ebersbach, G. Selective diplopia in Parkinson's disease: a special subtype of visual hallucination? Mov. Disord. 22, 1175–1178 (2007).

    Article  PubMed  Google Scholar 

  60. Matsui, H. et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease. J. Geriatr. Psychiatry Neurol. 19, 36–40 (2006).

    Article  PubMed  Google Scholar 

  61. Mosimann, U. P. et al. Visual perception in Parkinson disease dementia and Lewy body dementia. Neurology 63, 2091–2096 (2004).

    Article  CAS  PubMed  Google Scholar 

  62. Diederich, N. J., Raman, R., Leurgans, S. & Goetz, C. G. Progressive worsening of spatial and chromatic processing deficits in Parkinson's disease. Arch. Neurol. 59, 1249–1252 (2002).

    Article  PubMed  Google Scholar 

  63. Silva, M. F. et al. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Brain 128, 2260–2271 (2005).

    Article  CAS  PubMed  Google Scholar 

  64. Postuma, R. B., Lang, A. E., Massicotte-Marquez, J. & Montplaisir, J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66, 845–851 (2006).

    Article  CAS  PubMed  Google Scholar 

  65. Diederich, N. J. et al. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin. Neuropharmacol. 21, 289–295 (1998).

    CAS  PubMed  Google Scholar 

  66. Wink, B. & Harris, J. A model of the parkinsonian visual system: support for the dark adaptation hypothesis. Vision Res. 40, 1937–1946 (2000).

    Article  CAS  PubMed  Google Scholar 

  67. Lepore, F. E. Visual loss as a causative factor in visual hallucinations associated with Parkinson's disease. Arch. Neurol. 54, 799 (1997).

    Article  CAS  PubMed  Google Scholar 

  68. Rosenzweig, N. & Gardner, N. The role of input relevance in sensory isolation. Am. J. Psychiatr. 122, 920–928 (1966).

    Article  CAS  PubMed  Google Scholar 

  69. Barnes, J., Boubert, L., Harris, J., Lee, A. & David, A. S. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia 41, 565–574 (2003).

    Article  CAS  PubMed  Google Scholar 

  70. Lawrence, A. D., Goerendt, I. K. & Brooks, D. J. Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. Neuropsychologia 45, 65–74 (2007).

    Article  PubMed  Google Scholar 

  71. Sprengelmeyer, R. et al. Facial expression recognition in people with medicated and unmedicated Parkinson's disease. Neuropsychologia 41, 1047–1057 (2003).

    Article  CAS  PubMed  Google Scholar 

  72. Onofrj, M. et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol. Sci. 23 (Suppl. 2), S91–S94 (2002).

    Article  PubMed  Google Scholar 

  73. Uc, E. Y. et al. Impaired visual search in drivers with Parkinson's disease. Ann. Neurol. 60, 407–413 (2006).

    Article  PubMed  Google Scholar 

  74. Uc, E. Y. et al. Impaired navigation in drivers with Parkinson's disease. Brain 130, 2433–2440 (2007).

    Article  PubMed  Google Scholar 

  75. Nausieda, P. A., Weiner, W. J., Kaplan, L. R., Weber, S. & Klawans, H. L. Sleep disruption and psychosis in chronic levodopa therapy. Clin. Neuropharmacol. 5, 183–194 (1982).

    Article  CAS  PubMed  Google Scholar 

  76. Pacchetti, C. et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov. Disord. 20, 1439–1448 (2005).

    Article  PubMed  Google Scholar 

  77. Terzaghi, M. et al. Cognitive performance in REM sleep behavior disorder: a possible early marker of neurodegenerative disease? Sleep Med. 4, 343–351 (2008).

    Article  Google Scholar 

  78. Vendette, M. et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 69, 1843–1849 (2007).

    Article  CAS  PubMed  Google Scholar 

  79. Comella, C. L., Tanner, C. M. & Ristanovic, R. K. Polysomnographic sleep measures in Parkinson's disease patients with treatment- induced hallucinations. Ann. Neurol. 34, 710–714 (1993).

    Article  CAS  PubMed  Google Scholar 

  80. Nomura, T. et al. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Mov. Disord. 18, 812–817 (2003).

    Article  PubMed  Google Scholar 

  81. Arnulf, I. et al. Hallucinations, REM sleep, and Parkinson's disease. Neurology 55, 281–288 (2000).

    Article  CAS  PubMed  Google Scholar 

  82. Diederich, N. J., Goetz, C. G. & Stebbins, G. T. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov. Disord. 20, 130–140 (2005).

    Article  PubMed  Google Scholar 

  83. Gagnon, J. F., Postuma, R. B. & Montplaisir, J. Update on the pharmacology of REM sleep behavior disorder. Neurology 67, 742–747 (2006).

    Article  PubMed  Google Scholar 

  84. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003).

    Article  PubMed  Google Scholar 

  85. Jellinger, K. New developments in the pathology of Parkinson's disease. Adv. Neurol. 53, 1–16 (1990).

    CAS  PubMed  Google Scholar 

  86. Fronczek, R. et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130, 1577–1585 (2007).

    Article  PubMed  Google Scholar 

  87. Lal, S., Tesfaye, Y., Thavundayil, J. X., Skorzewska, A. & Schwartz, G. Effect of time-of-day on the yawning response to apomorphine in normal subjects. Neuropsychobiology 41, 178–180 (2000).

    Article  CAS  PubMed  Google Scholar 

  88. Dzirasa, K. et al. Dopaminergic control of sleep-wake states. J. Neurosci. 26, 10577–10589 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Bruguerolle, B. & Simon, N. Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin. Neuropharmacol. 25, 194–201 (2002).

    Article  PubMed  Google Scholar 

  90. Whitehead, D. L., Davies, A. D., Playfer, J. R. & Turnbull, C. J. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. Mov. Disord. 23, 1137–1145 (2008).

    Article  PubMed  Google Scholar 

  91. Manni, R. et al. Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology 59, 1979–1981 (2002).

    Article  CAS  PubMed  Google Scholar 

  92. Grossi, D. et al. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int. J. Geriatr. Psychiatry 20, 668–673 (2005).

    Article  PubMed  Google Scholar 

  93. Santangelo, G. et al. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Mov. Disord. 22, 2418–2425 (2007).

    Article  PubMed  Google Scholar 

  94. Ramírez-Ruiz, B., Junqué, C., Martí, M. J., Valldeoriola, F. & Tolosa, E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov. Disord. 21, 1483–1487 (2006).

    Article  PubMed  Google Scholar 

  95. Whitehead, D. L., Davies, A. D. M, Downes, J. J., Turnbull, C. J. & Playfer, J. R. Neuropsychological predictors of hallucinations in Parkinson's disease: Cognitive and perceptual biases [abstract 538]. Mov. Disord. 22 (Suppl. 16), S166 (2007).

    Google Scholar 

  96. Meppelink, A. M., Koerts, J., Borg, M., Leenders, K. L. & van Laar, T. Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Mov. Disord. 23, 1906–1912 (2008).

    Article  PubMed  Google Scholar 

  97. Ballard, C. G. et al. Fluctuations in attention. PD dementia vs DLB with parkinsonism. Neurology 59, 1714–1720 (2002).

    Article  CAS  PubMed  Google Scholar 

  98. Williams, D. R. & Lees, A. J. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 4, 605–610 (2005).

    Article  PubMed  Google Scholar 

  99. Papapetropoulos, S., Argyriou, A. A. & Ellul, J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J. Neurol. 252, 1223–1228 (2005).

    Article  PubMed  Google Scholar 

  100. Ramirez-Ruiz, B., Junque, C., Marti, M. J., Valldeoriola, F. & Tolosa, E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement. Geriatr. Cogn. Disord. 23, 281–288 (2007).

    Article  PubMed  Google Scholar 

  101. Goetz, C. G., Wuu, J., Curgian, L. & Leurgans, S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov. Disord. 21, 267–270 (2006).

    Article  PubMed  Google Scholar 

  102. Sandyk, R. & Gillman, M. A. Depression as a cause of hallucinations in Parkinson's disease. Clin. Neuropharmacol. 8, 199–200 (1985).

    Article  CAS  PubMed  Google Scholar 

  103. Aarsland, D., Ballard, C., Larsen, J. P. & McKeith, I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int. J. Geriatr. Psychiatry 16, 528–536 (2001).

    Article  CAS  PubMed  Google Scholar 

  104. de la Fuente-Fernandez, R., Núñez, M. A. & López, E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin. Neuropharmacol. 22, 226–230 (1999).

    CAS  PubMed  Google Scholar 

  105. Feldman, B., Chapman, J. & Korczyn, A. D. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol. Scand. 113, 14–17 (2006).

    Article  CAS  PubMed  Google Scholar 

  106. Goldman, J. G., Goetz, C. G., Berry-Kravis, E., Leurgans, S. & Zhou, L. Genetic plymorphisms in Parkinson's disease subjects with and without hallucinations. Arch. Neurol. 61, 1280–1284 (2004).

    PubMed  Google Scholar 

  107. Goetz, C. G. et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study. Arch. Neurol. 58, 209–213 (2001).

    Article  CAS  PubMed  Google Scholar 

  108. Onofrj, M. et al. HLA typing does not predict REM sleep behavior disorder and hallucinations in Parkinson's disease. Mov. Disord. 18, 337–340 (2003).

    Article  PubMed  Google Scholar 

  109. Kiferle, L. et al. Visual hallucinations in Parkinson's disease are not influenced by polymorphismas of serotonin 5-HT2A receptor and transporter genes. Neurosci. Lett. 422, 228–231 (2007).

    Article  CAS  PubMed  Google Scholar 

  110. Nguyen-Legros, J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg. Radiol. Anat. 10, 137–144 (1988).

    Article  CAS  PubMed  Google Scholar 

  111. Harnois, C. & Di Paolo, T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophtalmol. Vis. Sci. 31, 2473–2475 (1990).

    CAS  Google Scholar 

  112. Djamgoz, M. B., Hankins, M. W., Hirano, J. & Archer, S. N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res. 37, 3509–3529 (1997).

    Article  CAS  PubMed  Google Scholar 

  113. Inzelberg, R., Ramirez, J. A., Nisipeanu, P. & Ophir, A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 44, 2793–2797 (2004).

    Article  PubMed  Google Scholar 

  114. Maurage, C. A., Ruchoux, M. M., de Vos, R., Surguchov, A. & Destee, A. Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Ann. Neurol. 54, 542–547 (2003).

    Article  PubMed  Google Scholar 

  115. Devos, D. et al. ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. Neurology 65, 1107–1110 (2005).

    Article  CAS  PubMed  Google Scholar 

  116. Ramírez-Ruiz, B. et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur. J. Neurol. 14, 750–756 (2007).

    Article  PubMed  Google Scholar 

  117. Papapetropoulos, S., McCorquodale, D. S., Gonzalez, J., Jean-Gilles, L. & Mash, D. C. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat. Disord. 12, 253–256 (2006).

    Article  PubMed  Google Scholar 

  118. Snowden, R., Thompson, P. & Troscianko, T. Basic Vision. An Introduction to Visual Perception (Oxford University Press, Oxford, 2006).

    Google Scholar 

  119. Stebbins G. T. et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 63, 1409–1416 (2004).

    Article  CAS  PubMed  Google Scholar 

  120. Ramirez-Ruiz, B. et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov. Disord. 23, 2335–2343 (2008).

    Article  PubMed  Google Scholar 

  121. Nagano-Saito, A. et al. Visual hallucination in Parkinson's disease with FDG PET. Mov. Disord. 19, 801–806 (2004).

    Article  PubMed  Google Scholar 

  122. Oishi, N. et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65, 1708–1715 (2005).

    Article  CAS  PubMed  Google Scholar 

  123. Teunisse, R. J., Cruysberg, J. R., Hoefnagels, W. H., Verbeek, A. L. & Zitman, F. G. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 347, 794–797 (1996).

    Article  CAS  PubMed  Google Scholar 

  124. Ffytche, D. H. Visual hallucinations and the Charles Bonnet syndrome. Curr. Psychiatry Rep. 7, 168–179 (2005).

    Article  PubMed  Google Scholar 

  125. Ffytche, D. H. et al. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat. Neurosci. 1, 738–742 (1998).

    Article  CAS  PubMed  Google Scholar 

  126. Lhermitte, J. Syndrome de la calotte du pédoncule cérébral. Les troubles psycho-sensoriels dans les lésions du mésencéphale [French]. Rev. Neurol. (Paris) 38, 1359–1365 (1922).

    Google Scholar 

  127. Fletcher, P. C. & Frith, C. D. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat. Rev. Neurosci. 10, 48–58 (2009).

    Article  CAS  PubMed  Google Scholar 

  128. Collerton, D., Perry, E. & McKeith, I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav. Brain Sci. 28, 737–757 (2005).

    PubMed  Google Scholar 

  129. Hobson, J. A. & Pace-Schott, E. F. The cognitive neuroscience of sleep: neuronal systems, conciousness and learning. Nat. Rev. Neurosci. 3, 679–693 (2002).

    Article  CAS  PubMed  Google Scholar 

  130. Diederich, N. J., Pieri, V. & Goetz, C. G. Coping strategies for visual hallucinations in Parkinson's disease. Mov. Disord. 18, 831–832 (2003).

    Article  PubMed  Google Scholar 

  131. [No authors listed] Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 340, 757–763 (1999).

  132. Klein, C., Gordon, J., Pollak, L. & Rabey, J. M. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin. Neuropharmacol. 26, 8–11 (2003).

    Article  CAS  PubMed  Google Scholar 

  133. Pollak, P. et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry 75, 689–695 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Ondo, W. G., Levy, J. K., Vuong, K. D., Hunter, C. & Jankovic, J. Olanzapine for the treatment of dopaminergic induced hallucinations. Mov. Disord. 20, 1031–1035 (2005).

    Article  Google Scholar 

  135. Rabey, J. M., Prokhorov, T., Miniovitz, A., Dobronevsky, E. & Klein, C. Effect of quetiapine in psychotic PD patients: a double blind labeled study of 3 months' duration. Mov. Disord. 22, 313–318 (2007).

    Article  PubMed  Google Scholar 

  136. Merims, D., Balas, M., Peretz, C., Shabtai, H. & Giladi, N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin. Neuropharmacol. 29, 331–337 (2006).

    Article  CAS  PubMed  Google Scholar 

  137. Juncos, J. L. et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov. Disord. 19, 29–35 (2004).

    Article  PubMed  Google Scholar 

  138. Singh, S. & Wooltorton, E. Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ 173, 252 (2005).

    Article  PubMed  PubMed Central  Google Scholar 

  139. Howland, R. H. Risks and benefits of antipsychotic drugs in elderly patients with dementia. J. Psychosoc. Nurs. Ment. Health Serv. 46, 19–23 (2008).

    PubMed  Google Scholar 

  140. Goetz, C. G., Fan, W. & Leurgans, S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. Mov. Disord. 23, 1541–1545 (2008).

    Article  PubMed  Google Scholar 

  141. Kurita, A., Ochiai, Y., Kono, Y., Suzuki, M. & Inoue, K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J. Geriatr. Psychiatry Neurol. 16, 184–188 (2003).

    Article  PubMed  Google Scholar 

  142. Burn, D. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov. Disord. 21, 1899–1907 (2006).

    Article  PubMed  Google Scholar 

  143. Emre, M., Cummings, J. L. & Lane, R. M. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J. Alzheimers Dis. 11, 509–514 (2007).

    Article  CAS  PubMed  Google Scholar 

  144. Williams-Gray, C. H. & Barker, R. A. Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nat. Clin. Pract. Neurol. 3, 250–251 (2007).

    Article  PubMed  Google Scholar 

  145. Voon, V. & Lang, A. E. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin. Neuropharmacol. 27, 90–92 (2004).

    Article  PubMed  Google Scholar 

  146. Meco, G. & Bernardi, S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog. Neuropsycholpharmacol. Biol. Psychiatry 31, 311–331 (2007).

    Article  CAS  Google Scholar 

  147. Yamamoto, N., Oda, T. & Inada, T. Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam. Psychiatry Clin. Neurosci. 61, 691–694 (2007).

    Article  CAS  PubMed  Google Scholar 

  148. White, M. C., Sliverman, J. J. & Harbison, J. W. Psychosis associated with clonazepam therapy for blepharospasm. J. Nerv. Ment. Dis. 170, 117–119 (1982).

    Article  CAS  PubMed  Google Scholar 

  149. Sironi, V. A., Franzini, A., Ravagnati, L. & Marossero, F. Interinctal acute psychosis in temporal lobe epilepsy during withdrawal of anticonvulsant therapy. J. Neurol. Neurosurg. Psychiatry 42, 724–730 (1979).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Willis, G. L. & Turner, E. J. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol. Int. 24, 521–537 (2007).

    Article  PubMed  Google Scholar 

  151. Duvoisin, R. C. Parkinson's Disease. A Guide for Patient and Family (Raven, New York, 1991).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Center Hospitalier de Luxembourg, Luxembourg City, Luxembourg

    Nico J. Diederich

  2. Department of Neurology, CHU Henri Mondor, Créteil, France

    Gilles Fénelon

  3. Department of Neurological Sciences, Rush University Medical Center, Chicago, USA

    Glenn Stebbins & Christopher G. Goetz

Authors
  1. Nico J. Diederich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gilles Fénelon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glenn Stebbins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher G. Goetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nico J. Diederich.

Ethics declarations

Competing interests

Gilles Fénelon acts as a consultant for Boehringer–Ingelheim and Novartis Pharmaceuticals. Christopher G. Goetz has served as a consultant and advisory board member to Novartis Pharmaceuticals. The other authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Diederich, N., Fénelon, G., Stebbins, G. et al. Hallucinations in Parkinson disease. Nat Rev Neurol 5, 331–342 (2009). https://doi.org/10.1038/nrneurol.2009.62

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.62

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing